Controversies in the treatment of local and locally advanced gastric and esophageal cancers

Journal of Clinical Oncology

Volumn 33, Issue 16, 2015, Pages 1754-1759

  Cohen, Deirdre J ^a   Leichman, Lawrence ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; ESOPHAGUS CANCER; HUMAN; PERIOPERATIVE PERIOD; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PREOPERATIVE CHEMORADIOTHERAPY; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER; ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANIMAL; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGUS RESECTION; GASTRECTOMY; LOWER ESOPHAGUS SPHINCTER; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROCEDURES; STOMACH NEOPLASMS; SURGERY; TREATMENT OUTCOME;

ADENOCARCINOMA; ANIMALS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; GASTRECTOMY; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84937131863     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.7765     Document Type: Review

References (53)

1. Ferlay J, Soerjomataram I, Ervik M, et al: GLOBO-CAN 2012 version 1.0: Cancer Incidence and Mortality Worldwide - IARC CancerBase No. 11. Lyon, France, International Agency for Research on Cancer, 2013. http://globocan.iarc.fr.
2. Polk DB, Peek RM, Jr: Helicobacter pylori: Gastric cancer and beyond. Nat Rev Cancer 10:403-414, 2010
3. Wang DH, Souza RF: Biology of Barrett's esophagus and esophageal adenocarcinoma. Gastrointest Endosc Clin N Am 21:25-38, 2011
4. Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. CA Cancer J Clin 64:9-29, 2014
5. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
6. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202-209, 2014
7. Leichman L, Thomas CR, Jr: Squamous cell cancer of the esophagus: The forgotten one. Gastrointest Cancer Res 4:22-23, 2011
8. Kelsen DP, Ginsberg R, Pajak TF, et al: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339:1979-1984, 1998
9. Kelsen DP, Winter KA, Gunderson LL, et al: Long-term results of RTOG trial 8911 (USA Intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25:3719-3725, 2007
10. Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 359:1727-1733, 2002
11. Ychou M, Boige V, Pignon JP, et al: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715-1721, 2011
12. Urschel JD, Vasan H, Blewett CJ: A metaanalysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 183:274-279, 2002
13. Walsh TN, Noonan N, Hollywood D, et al: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462-467, 1996
14. Tepper J, Krasna MJ, Niedzwiecki D, et al: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26:1086-1092, 2008
15. van Hagen P, Hulshof MC, van Lanschot JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074-2084, 2012
16. Sjoquist KM, Burmeister BH, Smithers BM, et al: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol 12:681-692, 2011
17. Stahl M, Walz MK, Stuschke M, et al: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851-856, 2009
18. Leichman LP, Goldman BH, Bohanes PO, et al: S0356: A phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol 29:4555-4560, 2011
19. Roh JL, Wang XV, Manola J, et al: Clinical correlates of promoter hypermethylation of four target genes in head and neck cancer: A cooperative group correlative study. Clin Cancer Res 19:2528-2540, 2013
20. Taketa T, Correa AM, Suzuki A, et al: Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology 83:300-304, 2012
21. Waddell T, Verheij M, Allum W, et al: Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 40:584-591, 2014
22. Coburn N, Seevaratnam R, Paszat L, et al: Optimal management of gastric cancer: Results from an international RAND/UCLA expert panel. Ann Surg 259:102-108, 2014
23. Cardoso R, Coburn N, Seevaratnam R, et al: A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer. Gastric Cancer 15:S19-S26, 2012 (suppl 1)
24. Power DG, Schattner MA, Gerdes H, et al: Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer. J Am Coll Surg 208:173-178, 2009
25. Smyth E, Schöder H, Strong VE, et al: A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer 118:5481-5488, 2012
26. Sarela AI, Lefkowitz R, Brennan MF, et al: Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg 191:134-138, 2006
27. Gotoda T, Sasako M, Ono H, et al: Evaluation of the necessity for gastrectomy with lymph node dissection for patients with submucosal invasive gastric cancer. Br J Surg 88:444-449, 2001
28. Choi KS, Jung HY, Choi KD, et al: EMR versus gastrectomy for intramucosal gastric cancer: Comparison of long-term outcomes. Gastrointest Endosc 73:942-948, 2011
29. Bickenbach KA, Gonen M, Strong V, et al: Association of positive transection margins with gastric cancer survival and local recurrence. Ann Surg Oncol 20:2663-2668, 2013
30. Edge S, Byrd DR, Compton CC, et al: (eds): AJCC Cancer Staging Manual (ed 7). New York, NY, Springer-Verlag, 2010
31. Katai H, Yoshimura K, Maruyama K, et al: Evaluation of the New International Union Against Cancer TNM staging for gastric carcinoma. Cancer 88:1796-1800, 2000
32. Volpe CM, Driscoll DL, Douglass HO Jr: Outcome of patients with proximal gastric cancer depends on extent of resection and number of resected lymph nodes. Ann Surg Oncol 7:139-144, 2000
33. Songun I, Putter H, Kranenbarg EM, et al: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11:439-449, 2010
34. Inagawa S, Adachi S, Oda T, et al: Effect of fat volume on postoperative complications and survival rate after D2 dissection for gastric cancer. Gastric Cancer 3:141-144, 2000
35. Jiang L, Yang KH, Guan QL, et al: Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: A meta-analysis. J Surg Oncol 107:807-814, 2013
36. Enzinger PC, Benedetti JK, Meyerhardt JA, et al: Impact of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg 245:426-434, 2007
37. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20, 2006
38. Schuhmacher C, Gretschel S, Lordick F, et al: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 28:5210-5218, 2010
39. Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al: Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: Systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer 49:3149-3158, 2013
40. Bamboat ZM, Tang LH, Vinuela E, et al: Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Ann Surg Oncol 21:1678-1685, 2014
41. Messager M, Lefevre JH, Pichot-Delahaye V, et al: The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: A multicenter comparative study. Ann Surg 254:684-693, 2011; discussion 693
42. Piessen G, Messager M, Le Malicot K, et al: Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas: PRODIGE 19-FFCD1103-ADCI002. BMC Cancer 13:281, 2013
43. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730, 2001
44. Fuchs CS, Tepper JE, Niedzwiecki D, et al: Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol 29:256s, 2011 (suppl; abstr 4003)
45. Lee J, Lim do H, Kim S, et al: Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial. J Clin Oncol 30:268-273, 2012
46. Min C, Bangalore S, Jhawar S, et al: Chemoradiation therapy versus chemotherapy alone for gastric cancer after R0 surgical resection: A meta-analysis of randomized trials. Oncology 86:79-85, 2014
47. Huang YY, Yang Q, Zhou SW, et al: Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 Lymphadenectomy: A meta-analysis. PLoS One 8:e68939, 2013
48. Sasako M, Sakuramoto S, Katai H, et al: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387-4393, 2011
49. Bang YJ, Kim YW, Yang HK, et al: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet 379:315-321, 2012
50. Paoletti X, Oba K, Burzykowski T, et al: Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis. JAMA 303:1729-1737, 2010
51. Diaz-Nieto R, Orti-Rodríguez R, Winslet M: Post-surgical chemotherapy versus surgery alone for rsectable gastric cancer. Cochrane Database Syst Rev 9:CD008415, 2013
52. Tsuburaya A, Yoshida K, Kobayashi M, et al: Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): A phase 3 factorial randomised controlled trial. Lancet Oncol 15:886-893, 2014
53. Bajetta E, Floriani I, Bartolomeo MD, et al: Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer. J Clin Oncol 30:239s, 2012 (suppl; abstr LBA4001)